NCT00366522

Brief Summary

To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Timeline
Completed

Started Aug 2006

Shorter than P25 for phase_1 healthy

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2006

Completed
16 days until next milestone

First Submitted

Initial submission to the registry

August 17, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 21, 2006

Completed
11 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2006

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2006

Completed
Last Updated

August 7, 2009

Status Verified

August 1, 2009

Enrollment Period

1 month

First QC Date

August 17, 2006

Last Update Submit

August 6, 2009

Conditions

Healthy

Keywords

SafetyHealthyhealthy subjects

Outcome Measures

Primary Outcomes (1)

  • Safety and Tolerability

Interventions

LXR-623DRUG

Eligibility Criteria

Age19 Years - 50 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Healthy, men or women, aged 19-50 years
  • Exlcusion:
  • Use of any investigational or prescription drug within 30 days before study start
  • Any clinically imprtant medical disease or abnormal laboratory test results

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Unknown Facility

Lincoln, Nebraska, 68502, United States

Location

MeSH Terms

Interventions

2-(2-chloro-4-fluorobenzyl)-3-(4-fluorophenyl)-7-(trifluoromethyl)-2H-indazole

Study Officials

  • Medical Monitor

    Wyeth is now a wholly owned subsidiary of Pfizer

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

August 17, 2006

First Posted

August 21, 2006

Study Start

August 1, 2006

Primary Completion

September 1, 2006

Study Completion

September 1, 2006

Last Updated

August 7, 2009

Record last verified: 2009-08

Locations

US(1)